Skip to content
Any of the following:
- ICH due to head injury, in the opinion of the investigator.
- ICH secondary to structural causes (e.g. aneurysm, arteriovenous or cerebral cavernous malformation, tumour; and other secondary causes [e.g. cerebral venous thrombosis, arteritis]).
- ICH due to haemorrhagic transformation of an ischaemic stroke, according to the investigator.
- ICH symptom onset was within the last 24 hours.
- Patient is taking an antithrombotic drug (including prophylactic anticoagulation for venous thromboembolism) or traditional Chinese medicine (TCM), herbal or Ayurvedic medicine with antiplatelet or anticoagulant properties (including: ginkgo, Asian ginseng/red ginseng, danshan, safflower, turmeric, curcuma, Szechuan, cordalls and Chinese motherwort) following ICH , unless the patient and doctor believe it appropriate to discontinue use.
- Not available for follow-up over the next 1-3 years (e.g. no fixed home address)
- Other life-threatening illness (e.g. cancer) that precludes survival longer than one year.
- Pregnant, breast-feeding or of child-bearing potential and not using contraception.
- Enrolled in another interventional clinical research trial involving another investigational product (medicine) or device in which the steering committee of the other trial does not permit co-enrolment of patients in their trial into another trial (such as ASPIRING). If the other trial permits co-enrolment, then the patient can be enrolled also in ASPIRING.
